Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Innoviva, Inc. Director's Dealing 2011

Jun 8, 2011

32090_dirs_2011-06-08_02e14750-c128-4365-b777-8e2d7262b1ab.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2011-06-06

Reporting Person: DRAZAN JEFFREY M (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-06-06 Common Stock S 37344 $23.08 Disposed 78251 Direct
2011-06-07 Common Stock S 31907 $23.29 Disposed 46344 Direct

Footnotes

F1: Represents sales of (i) 15,000 shares held personally by the Reporting Person and (ii) 22,344 shares held by Sierra Ventures Associates VI, L.P. as nominee for the Reporting Person.

F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $23.00 to $23.23 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F3: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $23.25 to $23.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.